By Pension and Benefits Editorial Staff
The U.S. Supreme Court has ruled that ERISA does not preempt an Arkansas law that regulates the price at which pharmacy benefit managers (PBM) reimburse pharmacies for the cost of drugs covered by prescription-drug plans because the law amounts to cost regulation that does not bear an impermissible connection with or reference to ERISA. The court reversed the Eighth Circuit’s ruling that the law implicitly “related to” ERISA in violation of ERISA’s preemption provision.
Arkansas law. In 2015, Arkansas passed Act 900, which sought to protect pharmacies from being forced to sell drugs at a loss by, among other things, requiring that pharmacy benefit managers reimburse the pharmacies for generic drugs at a price at least equal to the pharmacies’ cost in acquiring the drug from a wholesaler. The state law also included what is known as a “decline-to-dispense” option, which permitted pharmacies to refuse to dispense a drug if they were to lose money on the transaction.
Lower courts. The Pharmaceutical Care Management Association (PCMA), a national trade association representing the 11 largest PBMs in the country, filed suit in Arkansas federal district court, asking the court to declare Act 900 preempted by both ERISA and Medicare Part D. The court ruled that ERISA preempted Act 900 but that Medicare Part D did not. The state appealed the part of the ruling finding that ERISA preempted the law, while the PCMA cross-appealed the determination that Medicare Part D did not.
In June 2018, the Eighth Circuit ruled that ERISA preempted Act 900 and Medicare Part D. The court determined both that the Arkansas law implicitly “related to” ERISA in violation of ERISA’s preemption provision and that the law “acted” with respect to standards that CMS had established in violation of Medicare Part D’s preemption provision.
In January 2020, the Supreme Court granted Arkansas Attorney General Leslie Rutledge’s petition for certiorari and heard the case in October 2020 on the issue of ERISA preemption.
No ERISA preemption. The Supreme Court ruled that Act 900 does not have an impermissible connection with an ERISA plan. The court explained that “not every state law that affects an ERISA plan or causes some disuniformity in plan administration has an impermissible connection with an ERISA plan. That is especially so if a law merely affects costs.” The court determined that Act 900 was merely a form of cost regulation. It requires PBMs to reimburse pharmacies for prescription drugs at a rate equal to or higher than the pharmacy’s acquisition cost. PBMs may well pass those increased costs on to plans, meaning that ERISA plans may pay more for prescription-drug benefits in Arkansas than in other states. However, “cost uniformity was almost certainly not an object of pre-emption.” In addition, the effect of Act 900 is not so acute that it will dictate plan choices.
The court also ruled that Act 900 does not “refer to” ERISA. “Act 900 does not act immediately and exclusively upon ERISA plans because it applies to PBMs whether or not they manage an ERISA plan. Indeed, the Act does not directly regulate health benefit plans at all, ERISA or otherwise. It affects plans only insofar as PBMs may pass along higher pharmacy rates to plans with which they contract,” the Court wrote. Likewise, ERISA plans are not essential to Act 900’s operation. Act 900 regulates PBMs whether or not the plans they service fall within ERISA’s coverage.
Source: Rutledge v. Pharmaceutical Care Management Association (U.S. Sup Ct).
Interested in submitting an article?
Submit your information to us today!Learn More